- Home
- NEXT vs NAMS Comparison
NEXT vs NAMS Comparison
Compare NEXT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEXT
- NAMS
- Stock Information
- Founded
- NEXT 2010
- NAMS 2019
- Country
- NEXT United States
- NAMS Netherlands
- Employees
- NEXT N/A
- NAMS N/A
- Industry
- NEXT Oil & Gas Production
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- NEXT Energy
- NAMS Health Care
- Exchange
- NEXT Nasdaq
- NAMS Nasdaq
- Market Cap
- NEXT 2.0B
- NAMS 2.2B
- IPO Year
- NEXT N/A
- NAMS N/A
- Fundamental
- Price
- NEXT $7.91
- NAMS $18.93
- Analyst Decision
- NEXT Hold
- NAMS Strong Buy
- Analyst Count
- NEXT 1
- NAMS 6
- Target Price
- NEXT $9.00
- NAMS $42.83
- AVG Volume (30 Days)
- NEXT 1.7M
- NAMS 689.2K
- Earning Date
- NEXT 05-06-2025
- NAMS 05-08-2025
- Dividend Yield
- NEXT N/A
- NAMS N/A
- EPS Growth
- NEXT N/A
- NAMS N/A
- EPS
- NEXT N/A
- NAMS N/A
- Revenue
- NEXT N/A
- NAMS $47,140,000.00
- Revenue This Year
- NEXT N/A
- NAMS N/A
- Revenue Next Year
- NEXT N/A
- NAMS N/A
- P/E Ratio
- NEXT N/A
- NAMS N/A
- Revenue Growth
- NEXT N/A
- NAMS 586.97
- 52 Week Low
- NEXT $4.27
- NAMS $14.06
- 52 Week High
- NEXT $9.71
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- NEXT 54.28
- NAMS 54.33
- Support Level
- NEXT $7.52
- NAMS $16.95
- Resistance Level
- NEXT $7.77
- NAMS $19.58
- Average True Range (ATR)
- NEXT 0.49
- NAMS 0.96
- MACD
- NEXT 0.04
- NAMS -0.03
- Stochastic Oscillator
- NEXT 56.51
- NAMS 76.20
About NEXT NextDecade Corporation
NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.